Brind.
  1. The Phase III VALUE clinical trial for a product developed by MediWound Ltd. is underway, involving a BARDA contract and sites across multiple countries, including the U.S. and Europe.

MediWound and NexoBrid participated in the EBA Congress, which was held in Berlin, Germany, in September 2025.

1 report, 1 independent Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MediWound and NexoBrid participated in the EBA Congress, which was held in Berlin, Germany, in September 2025.

Who's involved

What this event is mainly about
EBAMediWound (Germany)

Keep exploring

Part of

The Phase III VALUE clinical trial for a product developed by MediWound Ltd. is underway, involving a BARDA contract and sites across multiple countries, including the U.S. and Europe. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireMediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21